Re: Big News for Prostate Cancer Treatment

[Guest guest]

I start it next week in Boston

http://clinicaltrials.gov/ct2/show/NCT01347788?term=xl+184+and+prostate & rank=1

 

 

 

Has everyone heard about this?

 

There is a new drug in town from Exelixis called XL184 (cabozantinib) which was reported on in three big presentations at this year’s American Society of Clinical Oncology meeting in Chicago.

 

In ongoing Phase II clinical trials, XL184 has unprecedented activity in prostate cancer. It is also active in other cancers. Seattle Cancer Care Alliance has the Phase II XL184 trial open for prostate cancer patients now and will open it for ovarian cancer patients in the near future.

 

The excitement around this drug comes from its ability to cause regressions in bone scans—bone metastases unlike anything ever seen before. It also seems to be shrinking metastatic tumors in other sites.

 

“Until recently, no compound has resulted in marked improvements in bone metastases as measured by bone scans in advanced metastatic castrate resistant prostate cancer (mCRPC),” says Dr. Celestia Higano, medical oncologist at SCCA. “However, recent data with cabozantinib have shown marked effects on bone lesions on bone scan paired with alleviation of bone pain as well as shrinkage of measurable tumor lesions. Bone pain alleviation, supported by bone scan response assessment, may provide a possible endpoint for this compound that effectively addresses a clinically relevant, unmet medical need in men with prostate cancer.”

 

Sounds exciting!

 

Bob

 

-- Emersonwww.flhw.org

Every 2.25 minutes a man is diagnosed with prostate cancer.Every 16.5 minutes a man dies from the disease.

[Guest guest]

I start it next week in Boston

http://clinicaltrials.gov/ct2/show/NCT01347788?term=xl+184+and+prostate & rank=1

 

 

 

Has everyone heard about this?

 

There is a new drug in town from Exelixis called XL184 (cabozantinib) which was reported on in three big presentations at this year’s American Society of Clinical Oncology meeting in Chicago.

 

In ongoing Phase II clinical trials, XL184 has unprecedented activity in prostate cancer. It is also active in other cancers. Seattle Cancer Care Alliance has the Phase II XL184 trial open for prostate cancer patients now and will open it for ovarian cancer patients in the near future.

 

The excitement around this drug comes from its ability to cause regressions in bone scans—bone metastases unlike anything ever seen before. It also seems to be shrinking metastatic tumors in other sites.

 

“Until recently, no compound has resulted in marked improvements in bone metastases as measured by bone scans in advanced metastatic castrate resistant prostate cancer (mCRPC),” says Dr. Celestia Higano, medical oncologist at SCCA. “However, recent data with cabozantinib have shown marked effects on bone lesions on bone scan paired with alleviation of bone pain as well as shrinkage of measurable tumor lesions. Bone pain alleviation, supported by bone scan response assessment, may provide a possible endpoint for this compound that effectively addresses a clinically relevant, unmet medical need in men with prostate cancer.”

 

Sounds exciting!

 

Bob

 

-- Emersonwww.flhw.org

Every 2.25 minutes a man is diagnosed with prostate cancer.Every 16.5 minutes a man dies from the disease.

[Guest guest]

From the Advanced Prostate Cancer Blog :Cabozantinib, Promising, Still Controversial For the Treatment of Bone Mets in Prostate Cancer

http://advancedprostatecancer.net/?p=2777Read the post because the positive results might only be an artifact of the scans themselves. 

 

Has everyone heard about this? There is a new drug in town from Exelixis called XL184 (cabozantinib) which was reported on in three big presentations at this year’s American Society of Clinical Oncology meeting in Chicago.

 In ongoing Phase II clinical trials, XL184 has unprecedented activity in prostate cancer. It is also active in other cancers. Seattle Cancer Care Alliance has the Phase II XL184 trial open for prostate cancer patients now and will open it for ovarian cancer patients in the near future.

 The excitement around this drug comes from its ability to cause regressions in bone scans—bone metastases unlike anything ever seen before. It also seems to be shrinking metastatic tumors in other sites.

 “Until recently, no compound has resulted in marked improvements in bone metastases as measured by bone scans in advanced metastatic castrate resistant prostate cancer (mCRPC),” says Dr. Celestia Higano, medical oncologist at SCCA. “However, recent data with cabozantinib have shown marked effects on bone lesions on bone scan paired with alleviation of bone pain as well as shrinkage of measurable tumor lesions. Bone pain alleviation, supported by bone scan response assessment, may provide a possible endpoint for this compound that effectively addresses a clinically relevant, unmet medical need in men with prostate cancer.”

 Sounds exciting! Bob 

-- T Nowak, MA, MSWDirector for Advocacy and  Advanced Prostate Cancer Programs, Malecare Inc. Men Fighting Cancer, TogetherSurvivor - Recurrent Prostate, Thyroid, Melanoma and Renal Cancers

www.advancedprostatecancer.net - A blog about advanced and recurrent prostate cancerwww.malecare.org - information and support about prostate cancer

http://health.groups.yahoo.com/group/advancedprostatecancer/ - an online support group for men and their families diagnosed with advanced and recurrent prostate cancer

[Guest guest]

I start clinical trial next Wed.

To: ProstateCancerSupport Sent: Thursday, August 25, 2011 1:51 PMSubject: Big News for Prostate Cancer Treatment

Has everyone heard about this?

There is a new drug in town from Exelixis called XL184 (cabozantinib) which was reported on in three big presentations at this year’s American Society of Clinical Oncology meeting in Chicago.

In ongoing Phase II clinical trials, XL184 has unprecedented activity in prostate cancer. It is also active in other cancers. Seattle Cancer Care Alliance has the Phase II XL184 trial open for prostate cancer patients now and will open it for ovarian cancer patients in the near future.

The excitement around this drug comes from its ability to cause regressions in bone scans—bone metastases unlike anything ever seen before. It also seems to be shrinking metastatic tumors in other sites.

“Until recently, no compound has resulted in marked improvements in bone metastases as measured by bone scans in advanced metastatic castrate resistant prostate cancer (mCRPC),†says Dr. Celestia Higano, medical oncologist at SCCA. “However, recent data with cabozantinib have shown marked effects on bone lesions on bone scan paired with alleviation of bone pain as well as shrinkage of measurable tumor lesions. Bone pain alleviation, supported by bone scan response assessment, may provide a possible endpoint for this compound that effectively addresses a clinically relevant, unmet medical need in men with prostate cancer.â€

Sounds exciting!

Bob

[Guest guest]

Thanks for participating in this clinical trial. It's the only way to get conclusive data. Good Luck. Regards, tm.poxon I start clinical trial next Wed.To: ProstateCancerSupport Sent: Thursday, August 25, 2011 1:51 PMSubject: Big News for Prostate Cancer Treatment Has everyone heard about this? There is a new drug in town from Exelixis called XL184 (cabozantinib) which was reported on in three big presentations at this year’s American Society of Clinical Oncology meeting in Chicago. In ongoing Phase II clinical trials, XL184 has unprecedented activity in prostate cancer. It is also active in other cancers. Seattle Cancer Care Alliance has the Phase II XL184 trial open for prostate cancer patients now and will open it for ovarian cancer patients in the near future. The excitement around this drug comes from its ability to cause regressions in bone scans—bone metastases unlike anything ever seen before. It also seems to be shrinking metastatic tumors in other sites. “Until recently, no compound has resulted in marked improvements in bone metastases as measured by bone scans in advanced metastatic castrate resistant prostate cancer (mCRPC),†says Dr. Celestia Higano, medical oncologist at SCCA. “However, recent data with cabozantinib have shown marked effects on bone lesions on bone scan paired with alleviation of bone pain as well as shrinkage of measurable tumor lesions. Bone pain alleviation, supported by bone scan response assessment, may provide a possible endpoint for this compound that effectively addresses a clinically relevant, unmet medical need in men with prostate cancer.†Sounds exciting! Bob